Van ECK Associates Corp Sells 36,682 Shares of Sanofi $SNY

Van ECK Associates Corp reduced its holdings in Sanofi (NASDAQ:SNY) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 613,817 shares of the company’s stock after selling 36,682 shares during the period. Van ECK Associates Corp’s holdings in Sanofi were worth $28,972,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SNY. Waterfront Wealth Inc. boosted its position in shares of Sanofi by 0.4% in the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after purchasing an additional 214 shares during the last quarter. HighPoint Advisor Group LLC lifted its stake in Sanofi by 2.3% in the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after buying an additional 226 shares during the period. HM Payson & Co. lifted its stake in Sanofi by 3.4% in the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock valued at $342,000 after buying an additional 235 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its holdings in Sanofi by 4.7% during the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after buying an additional 238 shares during the last quarter. Finally, CreativeOne Wealth LLC grew its position in shares of Sanofi by 2.8% during the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after buying an additional 241 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SNY. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Finally, Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Sanofi currently has an average rating of “Hold” and an average price target of $62.67.

Sanofi Stock Performance

Shares of SNY opened at $43.94 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a twelve month low of $43.34 and a twelve month high of $59.17. The firm’s 50 day moving average price is $47.04 and its two-hundred day moving average price is $48.32. The firm has a market cap of $107.17 billion, a P/E ratio of 12.21, a PEG ratio of 1.14 and a beta of 0.45.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.